Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

• Published in: Journal of clinical pharmacology Vol. 48; no. 4; p. 475
• Main Authors: Small, David S, Farid, Nagy A, Payne, Christopher D, Weerakkody, Govinda J, Li, Ying G, Brandt, John T, Salazar, Daniel E, Winters, Kenneth J
• Format: Journal Article
• Language: English
• Published: England 01.04.2008
• Subjects: 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects; 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology; Adenosine Diphosphate - blood; Adolescent; Adult; Aged; Area Under Curve; Biological Availability; Cross-Over Studies; Drug Interactions; Female; Humans; Lansoprazole; Male; Middle Aged; Piperazines - adverse effects; Piperazines - pharmacokinetics; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - adverse effects; Platelet Aggregation Inhibitors - pharmacokinetics; Prasugrel Hydrochloride; Proton Pump Inhibitors - adverse effects; Proton Pump Inhibitors - pharmacology; Thiophenes - adverse effects; Thiophenes - pharmacokinetics; Ticlopidine - adverse effects; Ticlopidine - analogs & derivatives; Ticlopidine - pharmacokinetics

Prasugrel and clopidogrel, thienopyridine prodrugs, are each metabolized to an active metabolite that inhibits the platelet P2Y(12) ADP receptor. In this open-label, 4-period crossover study, the effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasug...